Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
S Qin, A Li, M Yi, S Yu, M Zhang, K Wu - Journal of hematology & oncology, 2019 - Springer
Angiogenesis has always been the topic of major scientific interest in the field of malignant
tumors. Nowadays, targeting angiogenesis has achieved success in various carcinomas by …
tumors. Nowadays, targeting angiogenesis has achieved success in various carcinomas by …
Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK
C Plummer, A Michael, G Shaikh, M Stewart… - British journal of …, 2019 - nature.com
Bevacizumab is an anti-vascular endothelial growth factor monoclonal antibody that may
prolong survival in ovarian and cervical cancer when given in combination with …
prolong survival in ovarian and cervical cancer when given in combination with …
Soluble E-cadherin promotes tumor angiogenesis and localizes to exosome surface
The limitations of current anti-angiogenic therapies necessitate other targets with
complimentary mechanisms. Here, we show for the first time that soluble E-cadherin (sE …
complimentary mechanisms. Here, we show for the first time that soluble E-cadherin (sE …
[HTML][HTML] Mirvetuximab soravtansine (IMGN853), a folate receptor alpha–targeting antibody-drug conjugate, potentiates the activity of standard of care therapeutics in …
JF Ponte, O Ab, L Lanieri, J Lee, J Coccia, LM Bartle… - Neoplasia, 2016 - Elsevier
Elevated folate receptor alpha (FRα) expression is characteristic of epithelial ovarian cancer
(EOC), thus establishing this receptor as a candidate target for the development of novel …
(EOC), thus establishing this receptor as a candidate target for the development of novel …
Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer
W Li, K Zhang, W Wang, Y Liu, J Huang… - Journal of Experimental …, 2024 - Springer
Background Ovarian cancer (OC) is a prevalent malignancy in the female reproductive
system, and developing effective targeted therapies for this disease remains challenging …
system, and developing effective targeted therapies for this disease remains challenging …
[HTML][HTML] Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human …
M Quanz, UB Hagemann, S Zitzmann-Kolbe… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Despite the recent advances in the treatment of ovarian cancer, it remains an area of high
unmet medical need. Epithelial ovarian cancer is associated with high levels of mesothelin …
unmet medical need. Epithelial ovarian cancer is associated with high levels of mesothelin …
Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: different models for different questions
NG Alkema, GBA Wisman, AGJ van der Zee… - Drug Resistance …, 2016 - Elsevier
High-grade serous ovarian cancer (HGSOC) has the highest mortality rate among all
gynecological cancers. Patients are generally diagnosed in an advanced stage with the …
gynecological cancers. Patients are generally diagnosed in an advanced stage with the …
[HTML][HTML] Increased PDGFR-beta and VEGFR-2 protein levels are associated with resistance to platinum-based chemotherapy and adverse outcome of ovarian cancer …
S Avril, Y Dincer, K Malinowsky, C Wolff, S Gündisch… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Despite frequent initial response rates of epithelial ovarian cancer to platinum-based
chemotherapy the majority of patients develop drug resistance. Our aim was to evaluate …
chemotherapy the majority of patients develop drug resistance. Our aim was to evaluate …
Prognostic features of the tumour microenvironment in oesophageal adenocarcinoma
Oesophageal adenocarcinoma (OAC) is a disease with an incredibly poor survival rate and
a complex makeup. The growth and spread of OAC tumours are profoundly influenced by …
a complex makeup. The growth and spread of OAC tumours are profoundly influenced by …
State of the art and up-and-coming angiogenesis inhibitors for ovarian cancer
N Singh, D Badrun, P Ghatage - Expert Opinion on …, 2020 - Taylor & Francis
Angiogenesis inhibitors have clearly shown activity in ovarian cancer in various settings;
however, preliminary data did not reflect significant survival benefit. Bevacizumab has been …
however, preliminary data did not reflect significant survival benefit. Bevacizumab has been …